Abstract
Collapsing response mediator proteins (CRMPs) are key for brain development and function. Here, we link CRMP1 to a neurodevelopmental disorder. We report heterozygous de novo variants in the CRMP1 gene in three unrelated individuals with muscular hypotonia, intellectual disability and/or autism spectrum disorder. Based on in silico analysis these variants are predicted to affect the CRMP1 structure. We further analyzed the effect of the variants on the protein structure/levels and cellular processes. We showed that the human CRMP1 variants are dominant-negative and impact the oligomerization of CRMP1 proteins. Moreover, overexpression of mutant-CRMP1 variants affect neurite outgrowth of murine cortical neurons. While altered CRMP1 levels have been reported in psychiatric diseases, genetic mutation in CRMP1 gene has never been linked to human disease. We report for the first-time mutations in the CRMP1 gene and emphasize its key role in brain development and function by linking directly to a human neurodevelopmental disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge the funding resources for this study: German Research Foundation (SFB665, SFB1315, FOR3004, AMK), the Sonnenfeld Stiftung (AMK, KLM), the Berlin Institute of Health (BIH, CRG1, AMK), the Charite (AMK, ER, LLB, KLM), and by grants-in-aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) (16K07062) (FN).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from all parents of the patients to participate in this study and publish the data of this research work. The human study adhered to the World Health Association Declaration of Helsinki (2013) and was approved by the local ethics committees of the Charite (approval no. EA1/212/08).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email addresses: ethiraj.ravindran{at}charite.de, arashiki.nobuto{at}twmu.ac.jp, lena-luise.becker{at}charite.de, takizawa.kohtaro{at}twmu.ac.jp, jonathan.levy{at}aphp.fr, thomas.rambaud{at}laboratoire-seqoia.fr, konstantin.makridis{at}charite.de, goshima{at}yokohama-cu.ac.jp, lina{at}cougarlab.org, m.vreeburg{at}mumc.nl, demeer.benedicte{at}chu-amiens.fr, adickma{at}gwdg.de, sander.stegmann{at}mumc.nl, huh{at}cougarlab.org, nakamura.fumio{at}twmu.ac.jp, angela.kaindl{at}charite.de
Data availability
All methods applied in this project are described in detail in the ‘Materials and Methods’section and the original data are presented as source file
